Abstract: In 2018, robot-assisted radical cystectomy will enter its 15th year. In an era where an effort is being made to standardize complication reporting and videos of the procedure are readily available, it is inevitable and justified that like everything novel, robot-assisted radical cystectomy should be scrutinized against the gold standard, open radical cystectomy. The present comparison is focused on several parameters: oncological, functional and complication outcomes, and direct and indirect costs. Metaanalysis and prospective randomized trials comparing robot-assisted radical cystectomy versus open radical cystectomy have been published, showing an oncological equivalence and in some cases an advantage of robot-assisted radical cystectomy in terms of postoperative morbidity. In the present review, we attempt to update the available knowledge on this debate and discuss the limitations of the current evidence that prevent us from drawing safe conclusions.
Introduction
RC is arguably the most challenging and morbid operation in surgical uro-oncology. It requires the expertise of an experienced surgeon and an experienced surgical team that will reflect on the oncological, as well as the functional outcome, with the lowest possible intraand postoperative complications. ORC has been considered the gold standard treatment for muscle-invasive bladder cancer. Its surgical principles were founded in the late 1940s by Marshall and Whitmore, and as a procedure, it has been evolving and refined until now. However, since the introduction of minimally invasive surgery, at first with conventional laparoscopy and later with robot-assisted surgery, RC has entered a new era, in an effort to minimize complications. The oncological outcome has not been improved over the past three decades, and surgical technique is not likely to change the survival outcomes. 1 The utilization of RARC has increased in a rapid way in the USA and globally, more than 25-fold, from 0.7% to 18.5% in 2012. 2 Despite this, RARC is still a "teenager." The first cases were carried out in 2003, and as a procedure, it was still considered as experimental until 2012. 3 That year, the European Association of Urology Guidelines stated that RARC is not a proven alternative to open surgery. One year later, in 2013, the same guidelines changed the statement for RARC, characterizing it as a feasible and safe procedure; 4 whereas since 2014, RARC was not inferior to ORC in terms of complications, and short-and intermediate term oncological outcomes. 5 The above statements were all based on small, comparative, but heterogeneous studies, with several limitations. Other conclusions were made by comparing current RARC series with historical data from large reference centers. The need for prospective RCTs was apparent. For that reason, during 2010-2016, four RCTs have been published, which tried to provide a definitive answer to the debate. [6] [7] [8] [9] However, even with data from RCTs, which represent a high-level of evidence (grade 2b), the limitations of the studies still created skepticism, and highlighted the problematic conception and realization of a high-quality, non-biased RCT.
In this review, we will try to present the available knowledge on the RARC versus ORC debate and shed some more light on the limitations that prevent us from obtaining a definitive answer.
The comparison will be focused on perioperative outcomes, such as complications; hospital LOS; oncological outcomes (positive surgical margins, lymph node yield, survival measures); functional outcomes, such as continence and potency, which can be applied to neobladder diversions only; and cost analysis.
Perioperative outcomes
Even in the most experienced hands and high-volume centers, the rates of overall 90-day complications are high, reaching up to 64%, 10 whereas the rates of long-term complications can be as high as 40.8%. 11 Before examining complication outcomes, we need to focus on the confounders that most studies show. Patient and tumor characteristics are usually treated by propensity scored matching, in order to decrease selection bias. Nevertheless, significant confounders lie on the type of urinary diversion (conduit vs neobladder), the use of extracorporeal or totally intracorporeal technique for construction of the diversion and the application of ERP. These three elements could be critical for the postoperative outcome and for the optimization of this challenging surgical journey.
Significant hesitancy was seen globally in adopting the totally intracorporeal technique for bowel handling and reconstruction of the urinary diversion in the fear of increasing complications. On the contrary, in the light of data published by the IRCC, it seems that shifting to the intracorporeal technique might be justified. In this multicenter, retrospective review of 167 patients undergoing RARC with intracorporeal diversion (ileal conduit: 106; neobladder: 61) and 768 patients undergoing RARC with extracorporeal diversion (ileal conduit: 570; neobladder: 198), the intracorporeal patients were at a lower risk of experiencing a postoperative complication at 90 days (32%; odds ratio 0.68; 95% CI 0.50-0.94; P = 0.02). 12 In addition, the authors reported a statistically significant lower risk for gastrointestinal and infectious complications in favor of the intracorporeal approach, which are the most common major complications at 90 days. 11 The totally intracorporeal technique provides some advantages. The bowel stays inside the abdomen, no hypothermia or loss of fluids through osmosis occurs, less bleeding, less need for ureteral dissection, and less traction to the bowel and ureters.
The ERP is also beneficial for the patient's postoperative course. This concept has been known for many years. It was introduced by open colorectal surgeons, and recently gained significant interest because of RARC. 13 Minimally invasive surgery has been added as one of the 22 elements of ERP; 14 thus, robotic surgeons try to apply ERP, but the fact remains that it is underutilized. ERP has shown that it decreases LOS, postoperative ileus, complications and risk for readmission at 30 days. 15 Having said this, we understand beforehand, that the absence of ERP and the intracorporeal approach might introduce bias and create problems in the interpretation of the results. If not all, many studies including all published RCTs, did not use the totally intracorporeal approach, did not describe thoroughly their clinical pathway or the use of ERP and in many cases, the diversion commonly used is the ileal conduit and not the neobladder. Thus, the ideal situation would be to compare the totally intracorporeal RARC with ORC in the same type of urinary diversion and applying ERP.
We examined systematic analyses, meta-analyses and large national healthcare registries that were published over the years. Since 2013, we have found 14 such analyses. 2, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Two of them are actually meta-analyses of the four published RCTs. 24, 29 Table 1 summarizes their results in a better or worse fashion, which represents a statistically significant difference between RARC and ORC. The studies are overlapping, but in a 4-year period, during which the RARC studies are becoming more "mature," it seems that there is a consistent pattern in the results. Having in mind the aforementioned limitations, one could speculate that RARC is better for blood loss, transfusion rates, LOS and overall complications, which is something expected from a minimally invasive procedure.
Blood loss and transfusion are classified as grade 2 complications in the Clavien-Dindo classification system. They are minor complications in severity, and in that sense, they are downplayed in complication reporting. However, blood loss leading to transfusion is a major predictor of worse oncological prognosis. ORC with a median higher blood loss of >500 cc than RARC could lead to a blood transfusion. In Table 2 , the range of blood loss in ORC versus RARC is 475-1522 cc versus 275-675 cc, which highlights the higher possibility for transfusion in ORC.
A recent meta-analysis of 7080 patients from six eligible, retrospective studies and a mean follow-up period of 39 months suggested that transfusion in patients who underwent RC was associated with increased overall mortality, cancer-specific mortality and cancer recurrence (HR 1.19, 95% CI 1.11-1.27, P < 0.00001; 1.17, 95% CI 1.06-1.30, P = 0.002; 1.14, 95% CI 1.03-1.27, respectively). 30 Furthermore, timing of transfusion is also discussed. Abel et al. reported in a cohort of 360 patients that the intraoperative and not the postoperative transfusion was correlated with worse OS and recurrence. 31 In contrast, in a very recent study from Buchner et al. in 722 patients with 26 months of follow up, they saw a negative and dose-dependent impact of transfusion, irrespective of timing and stage of the bladder cancer. 32 The same result was recorded by Siemens et al., who apart from worse survival, they also recorded an association of transfusion with poorer early outcomes, such as LOS and re-admission rates. 33 The only study until now that did not show any effect of transfusion in the end-point of distant recurrences was the study by Moschini et al., in a retrospective series of 1060 patients from two centers. 34 The reason for this conflicting negative impact of transfusion is probably due to the induced immunosuppression and the association of blood compatibility with infections.
The four RCTs have published their early outcomes, and the recent meta-analysis by Tan et al. of those RCTs concluded that RARC is better for blood loss and wound complications, and worse for operation time. 29 No other difference in terms of postoperative morbidity, PSM, lymph node yield, and LOS was found between RARC and ORC.
It is expected that it is very difficult to design an ideal RCT when dealing with surgical procedures, so the authors should be congratulated for their efforts. The apparent differences consist of the accrual of patients, the patient and tumor characteristics, the level of experience of the participating surgeons, the volume of each participating center, the clinical pathway used, the type of diversion, the extra-or intracorporeal approach. Furthermore, the small number of patients, the short follow up and the non-multicenter character of the design add up to the limitations.
The RCT with the highest number of patients is the study by the Memorial Sloan Kettering Cancer Center in New York. 6 However, even in this elegant study, there were several limitations: it was a single-center trial, with a rather small number of patients (58 ORC and 60 RARC). There was a large difference in the number of pre-study cystectomies carried out by the RARC and open surgeons, respectively. All RARC were carried out in an extracorporeal fashion; approximately half of the patients in both arms received a neobladder and most importantly, the study was designed to detect a difference of 20% in Clavien grade 2-5 complications between ORC and RARC. The authors acknowledged the fact that if the difference was set to 10% or 15%, perhaps they would have had a different outcome. The same limitations also apply to the other three RCTs; Thus, until the RAZOR (RAndomiZed Open vs Robotic cystectomy) study publishes its results, which will be the largest RCT with at least 320 patients, from 15 participating institutions, with a primary end-point of 2-year progressionfree survival, aiming at the non-inferiority of RARC versus ORC, any definitive conclusions are still unsafe. 35 
Oncological outcomes
The accumulating oncological outcome data for RARC is supported by encouraging short-term and intermediate outcome reports. Table 3 summarizes data from large ORC and RARC series, as well as head-to-head series, including the four RCTs and the recent RCT meta-analysis. 2, [6] [7] [8] [9] 21, 23, 84, 85 The main oncological end-points that can be evaluated are the lymph node yields, the positive surgical margin rates and the survival rates (overall, cancer-specific, recurrence-free).
Using the aforementioned results and by comparing them with data from historical cohorts of high-volume reference centers (Table 3) , it seems that that RARC does not provide an inferior oncological result to ORC. 23 To be more specific, the mean 5-year OS is similar in both approaches, ranging approximately between 60% and 70%, especially in highvolume reference centers. 21, 23, 36, 39, 40, 66 Regarding lymph node dissection, which is a significant and time-consuming part of the operation from an oncological standpoint, it has been established that RARC can achieve a similar lymph node count to ORC. A super-extended lymph node dissection is feasible and safe with the robot. Recently, Li et al. published a systematic review by pooling data from nine comparative RARC versus ORC studies. 16 After counting lymph nodes excised in 874 patients, a statistically significant difference was shown in favor of RARC. The same conclusion was published by four systematic analyses, between 2013 and 2017. In contrast, the RCTs and their meta-analysis did not show any difference.
Apart from lymph node dissection, it is also critical to extirpate the disease fully, as reflected by the margin status. The first meta-analysis showed that positive surgical margins have a negative and statistically significant impact in the survival outcome measures. 64 Most of the studies show a trend for better outcomes of RARC, but these are not statistically significant. Furthermore, all systematic reviews and the meta-analysis of RCTs concur that RARC and ORC have equal margin rates. The systematic review for RARC published in 2015 reported PSM rates of 5.6% (0-26%). 23 However, when the analysis was stratified by surgeon experience in series of >100 patients, margin rates fluctuated between 4% and 9%. Positive margins were reported in 1-1.5% and 0-25% in pT2 and pT3-4 disease, respectively. The IRCC database of 939 patients recorded an 8% positive margin rate. 21 Traditional ORC series from highvolume centers have published similar overall positive margin rates (4.2-8.6%; Table 4 ).
Yuh et al. have published a systematic review of the oncological outcomes of RARC, using the IRCC dataset. 23 The lymph node yield was 19 (range and the N + rate was 22%. Five-year DFS, CSS and OS rates were 53-74%, 66-80% and 39-66%, respectively. The differences between ORC and RARC were not statistically significant, but the studies used showed a significant heterogeneity and overlapping; thus, we need to appreciate the conclusions with caution.
The IRCC updated the long-term oncological outcomes of RARC. 21 In this retrospective analysis of prospective data of 702 patients, with a median follow up of 44 months, the 5-year recurrence-free survival, CSS and OS were 67%, 75% and 50%, respectively. These results were encouraging, considering that 38% of the cohort had advanced disease (pT3-4) and 21% were lymph node-positive.
Snow-Lisy et al. reported the oncological outcomes of RARC and laparoscopic radical cystectomy at up to 12-year follow up, which represents the longest follow up to date. 65 The survival rates were similar between the three approaches, reaching approximately a 5-year CSS of 70%.
Collins et al. reported on Karolinska's first 113 consecutive totally intracorporeal RARC carried out since 2003. 66 The mean number of lymph nodes excised was 21 (range 0-57). A total of 20% of patients had pN1 disease. The PSM rate was 5.3%. Median follow up was up to 9 years with a median of 25 months (range 3-107 months). Using KaplanMeier analysis, CSS was 81% at 3 years and 67% at 5 years.
Αn interesting study comparing ORC with RARC with totally intracorporeal urinary diversion was published by Tan et al. 67 A total of 94 and 90 patients were subjected to RARC and ORC, respectively, with 33.8 months of follow up. They found no difference in the primary outcome of the study, which was the recurrence-free survival. Also, no difference was found in the recurrence sites.
Recurrence sites is a debatable issue, as a recent comparison of extracorporeal RARC versus ORC by Nguyen et al. showed that RARC had higher extrapelvic and peritoneal carcinomatosis. 68 In this study, peritoneal carcinomatosis was seen in 21% of the patients compared with 8% in ORC. All of the patients with peritoneal spread had pT3-4 disease. We have to keep in mind though that the aforementioned study received criticism for statistical flaws, which might have led to a false conclusion. 69 In addition, both the IRCC and the European Association of Urology Robotic Urology Section Group have reported that peritoneal carcinomatosis is very rare during RARC (1% and 0.7%, respectively), similarly to open surgery. 70, 86 Thus, the issue of potential peritoneal tumor spread as a result of the effect of pneumoperitoneum warrants further research. Furthermore, a recent analysis from the IRCC showed that early bladder cancer recurrence is not dependent on the use of open or robotic surgery. 70 These conflicting results highlight the fact that in order to improve the prognosis and survival of bladder cancer patients, we need to augment RC with better high-level of evidence multimodality regimens, better chemotherapy in a neoadjuvant and adjuvant setting, and better selection of patients that will receive the maximum benefit from RC and/ or chemotherapy. 66 Daytime continence ranged between 64% and 100%, nocturnal continence between 17% and 72%, and potency at 81% in the nerve-sparing patients. The 2012 European Association of Urology International Consultation on Bladder Cancer, which reviewed the data published on urinary diversion between 1970 and 2012, concluded that in patients with ORC and orthotopic bladder substitution, daytime and night-time continence was achieved in 85-90% and 60-80%, respectively. 10 The Karolinska results on continence and potency were also published by Tyritzis et al. 71 In the first 70 neobladders, 19 male (90.5%) and two out of three (66.7%) female patients were continent (0-1 pad/day) at 12 months. A total of 16 (76.2%) of the nerve-spared patients were potent with or without PDE5 medication at 12 months. RCTs with sufficient power are awaited. Table 4 shows the available RARC studies of neobladders with published functional outcomes. 53, [71] [72] [73] [74] [75] [76] [77] There is only one study to date that included urodynamic data when comparing RARC with intracorporeal neobladder with ORC with neobladder, by Satkunasivam et al. 77 The authors stated that the RARC neobladder had similar urodynamic characteristics to the ORC neobladder, but the RARC daytime continence was inferior to ORC. Patient urinary bother was similar between the two procedures. The study had limitations: it was retrospective, with a small number of patients (28 RARC, 79 ORC) and a very short follow-up period for RARC (9.4 months compared with 62.1 months for ORC).
Cost outcomes
Estimation of cost can be challenging. Each study on cost usually reflects the status in the individual health system, as there are differences between the countries in terms of drug use, hospitalization, coverage of the public insurance system and several other parameters. Another confounder is the lack of the indirect costs estimation. RC could be a morbid procedure, which leads to significant readmission rates and additional treatments. These are the indirect costs that are not taken into account. In addition, RARC is limited by the high acquisition and maintenance fees of the robot, which are not also considered during a cost analysis. Table 5 summarizes the studies that have been published so far and the conclusion that the authors made. 2, 6, 17, [78] [79] [80] [81] [82] In the largest comparative study for cost to date, Lee et al. concluded that the per-case costs of RARC with ileal conduits, cutaneous continent diversion and neobladders were $20 659, $22 102 and $22 685, respectively, compared with $25 505, $22 697 and $20 719 for ORC. 78 Furthermore, the prevalent cost driver in the study was hospital stay. Another study by Leow et al., after carrying out a threshold analysis, suggested that RARC might become a cost-efficient procedure if the operation time drops to <6 h and the hospital stay to <7 days. 17 This study calculated comprehensively all 90-day direct costs, from operating room to supplies and imaging. The reason for the above result was that RARC had fewer major complications compared with ORC.
The most recent cost analysis was published in 2016, and it was based on the Surveillance, Epidemiology and End Results Program-Medicare linked data. 2 28 41.6 † 37.5 † NA †Definition of continence is almost dry to slightly wet. An update on health economics for muscle-invasive bladder cancer showed that the economic burden would be decreased if the surgical complications could be reduced and if neoadjuvant chemotherapy could be utilized more, as it improves the quality of life and survival of the patients. 83 
Conclusions
Muscle-invasive bladder cancer is an aggressive tumor with high mortality. Even though tumor biology and not the surgeon with his/her tools is the most important oncological factor, we cannot undermine the fact that also the surgical technique might provide assistance to the final outcome. Initial studies imply that RARC performs better in terms of blood loss, transfusion rates and length of stay. When ERP along with the intracorporeal technique are also applied, postoperative morbidity could be further reduced. It is likely to expect that the oncological outcome will be improved in the future by better chemotherapy protocols, better patient selection and patient preparation for the procedure. Unfortunately, current evidence, hampered by obvious and expected limitations, does not allow for precise conclusions on the ORC versus RARC debate. The authors have the feeling that the debate should refocus in a different setting, by not asking which approach is better, but by asking which multimodal treatment would provide the most benefit.
